MTIX Micro Therapeutics (MM)

PLYMOUTH, Minn., or IRVINE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV) and its majority-owned subsidiary Micro Therapeutics, Inc. (MTI) (NASDAQ:MTIX), will each release its 2005 third-quarter financial results on October 27, 2005 before regular market trading hours. The companies will host a joint conference call and Webcast the same day at 8:00 a.m. CT (9:00 a.m. ET; 6:00 a.m. PT). Management from ev3 first will review its financial and operating results and future outlook to be followed by a question and answer session. At approximately 8:25 a.m. CT, MTI management will review its financial and operating results and provide its future outlook. The call then will be opened for questions about MTI. The conference call will be available to interested parties through a live audio Webcast at http://www.ev3.net/ as well as http://www.1mti.com/ where it will be archived and accessible for approximately 90 days. About Micro Therapeutics, Inc. Micro Therapeutics develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of vascular disease. The company is focused on catheter-based, or endovascular, technologies for the minimally invasive treatment of neurovascular disorders of the brain associated with stroke. About ev3 Inc. ev3 Inc. is a global medical device company focused on endovascular technologies for the minimally invasive treatment of vascular diseases and disorders. DATASOURCE: ev3 Inc. CONTACT: Pat Spangler, CFO of ev3 Inc., +1-763-398-7000, or Thomas C. Wilder, CEO of Micro Therapeutics, Inc., +1-949-837-3700, or Marian Briggs or Nancy Johnson, both of Padilla Speer Beardsley, +1-612-455-1700, or Rob Whetstone or Robert Jaffe, both of PondelWilkinson Inc., +1-310-279-5980 Web site: http://www.ev3.net/ http://www.1mti.com/

Copyright